Injectable anabolic steroid compound recalled for lack of sterility assurance
Talon Compounding Pharmacy is recalling an injectable testosterone cypionate compound because the manufacturer cannot assure the product is sterile. The affected vials were distributed across the United States.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA classified this as a Class II recall. The hazard is a lack of sterility assurance in an injectable product, which poses a risk of serious infection and harm. No reported illnesses or injuries are stated in the source, so the score is capped at 3 per the rubric; however, the theoretical risk from a non-sterile injectable justifies the "High" label.
Plain-English summary
Vita Pharmacy, LLC (dba Talon Compounding Pharmacy) is recalling TEST CYPIONATE 200MG/ANASTROZOLE 0.5MG/DUTASTERIDE 1.5MG/ML IN OIL INJECTABLE (4 vials) because the product lacks assurance of sterility.
The recalled product was distributed throughout the United States, including Washington, D.C. and Puerto Rico. The affected lots are T1007012021:96 (BUD 12/28/2021) and T1008192021:04 (BUD 02/15/2022).
Consumers who have received this product should consult their healthcare provider or pharmacist immediately for guidance. The product is prescription-only and distributed through pharmacies.
The recalled product
- Product
- TEST CYPIONATE 200MG/ANASTROZOLE 0.5MG/DUTASTERIDE 1.5MG/ML IN OIL INJECTABLE, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247
- Manufacturer
- Vita Pharmacy, LLC dba Talon Compounding Pharmacy
- Category
- Drug — Compounded Injectable
- Hazard
- lack-of-sterility
- injectable-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: T1007012021:96 BUD: 12/28/2021
- T1008192021:04 BUD: 02/15/2022
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27